Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

K H Bohuslavizki; Winfried Brenner; S Lassmann; S Tinnemeyer; G Tönshoff; C Sippel; H Wolf; M Clausen; E Henze

Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

Standard

Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. / Bohuslavizki, K H; Brenner, Winfried; Lassmann, S; Tinnemeyer, S; Tönshoff, G; Sippel, C; Wolf, H; Clausen, M; Henze, E.

In: NUCL MED COMMUN, Vol. 17, No. 8, 8, 1996, p. 681-686.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bohuslavizki, KH, Brenner, W, Lassmann, S, Tinnemeyer, S, Tönshoff, G, Sippel, C, Wolf, H, Clausen, M & Henze, E 1996, 'Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.', NUCL MED COMMUN, vol. 17, no. 8, 8, pp. 681-686. <http://www.ncbi.nlm.nih.gov/pubmed/8878127?dopt=Citation>

APA

Bohuslavizki, K. H., Brenner, W., Lassmann, S., Tinnemeyer, S., Tönshoff, G., Sippel, C., Wolf, H., Clausen, M., & Henze, E. (1996). Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. NUCL MED COMMUN, 17(8), 681-686. [8]. http://www.ncbi.nlm.nih.gov/pubmed/8878127?dopt=Citation

Vancouver

Bohuslavizki KH, Brenner W, Lassmann S, Tinnemeyer S, Tönshoff G, Sippel C et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. NUCL MED COMMUN. 1996;17(8):681-686. 8.

Bibtex

@article{b3f26b70759942de8c7523e98ed0b348,

title = "Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.",

abstract = "This study was undertaken to quantify salivary gland parenchymal damage after radioiodine treatment with a standard protective regimen of ascorbic acid. Altogether, 106 patients underwent quantitative salivary gland scintigraphy with 99Tcm-pertechnetate prior to and 3 months after radioiodine therapy. Parenchymal function was quantified by calculating 99Tcm-pertechnetate uptake 13 min post-injection. Patients received 131I doses ranging from 400 MBq to 24 GBq (cumulative). Among the patients who received large doses of 131I, severe parenchymal destruction could be visually analysed as well as quantitatively evaluated. In contrast, after low-dose radioiodine treatment, mild parenchymal impairment was demonstrated by quantitative evaluation only. In conclusion, standardized quantitative salivary gland scintigraphy is essential for the reliable detection of mild parenchymal malfunction. Despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine therapy induces loss of salivary gland parenchymal function even with low doses of 131I.",

author = "Bohuslavizki, {K H} and Winfried Brenner and S Lassmann and S Tinnemeyer and G T{\"o}nshoff and C Sippel and H Wolf and M Clausen and E Henze",

year = "1996",

language = "Deutsch",

volume = "17",

pages = "681--686",

journal = "NUCL MED COMMUN",

issn = "0143-3636",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

RIS

TY - JOUR

T1 - Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.

AU - Bohuslavizki, K H

AU - Brenner, Winfried

AU - Lassmann, S

AU - Tinnemeyer, S

AU - Tönshoff, G

AU - Sippel, C

AU - Wolf, H

AU - Clausen, M

AU - Henze, E

PY - 1996

Y1 - 1996

N2 - This study was undertaken to quantify salivary gland parenchymal damage after radioiodine treatment with a standard protective regimen of ascorbic acid. Altogether, 106 patients underwent quantitative salivary gland scintigraphy with 99Tcm-pertechnetate prior to and 3 months after radioiodine therapy. Parenchymal function was quantified by calculating 99Tcm-pertechnetate uptake 13 min post-injection. Patients received 131I doses ranging from 400 MBq to 24 GBq (cumulative). Among the patients who received large doses of 131I, severe parenchymal destruction could be visually analysed as well as quantitatively evaluated. In contrast, after low-dose radioiodine treatment, mild parenchymal impairment was demonstrated by quantitative evaluation only. In conclusion, standardized quantitative salivary gland scintigraphy is essential for the reliable detection of mild parenchymal malfunction. Despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine therapy induces loss of salivary gland parenchymal function even with low doses of 131I.

AB - This study was undertaken to quantify salivary gland parenchymal damage after radioiodine treatment with a standard protective regimen of ascorbic acid. Altogether, 106 patients underwent quantitative salivary gland scintigraphy with 99Tcm-pertechnetate prior to and 3 months after radioiodine therapy. Parenchymal function was quantified by calculating 99Tcm-pertechnetate uptake 13 min post-injection. Patients received 131I doses ranging from 400 MBq to 24 GBq (cumulative). Among the patients who received large doses of 131I, severe parenchymal destruction could be visually analysed as well as quantitatively evaluated. In contrast, after low-dose radioiodine treatment, mild parenchymal impairment was demonstrated by quantitative evaluation only. In conclusion, standardized quantitative salivary gland scintigraphy is essential for the reliable detection of mild parenchymal malfunction. Despite the standard protection regimen using ascorbic acid as a sialogogue, radioiodine therapy induces loss of salivary gland parenchymal function even with low doses of 131I.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 681

EP - 686

JO - NUCL MED COMMUN

JF - NUCL MED COMMUN

SN - 0143-3636

IS - 8

M1 - 8

ER -